Literature DB >> 12727706

Placental passage of antidepressant medications.

Victoria Hendrick1, Zachary N Stowe, Lori L Altshuler, Sun Hwang, Emily Lee, Desiree Haynes.   

Abstract

OBJECTIVE: This study determined the placental transfer of antidepressants and their metabolites.
METHOD: A total of 38 pregnant women taking citalopram, fluoxetine, paroxetine, or sertraline participated. Maternal and umbilical cord blood samples were obtained to determine antidepressant and metabolite concentrations.
RESULTS: Antidepressant and metabolite concentrations were detectable in 86.8% of umbilical cord samples. The mean ratios of umbilical cord to maternal serum concentrations ranged from 0.29 to 0.89. The lowest ratios were for sertraline and paroxetine; the highest were for citalopram and fluoxetine. Maternal doses of sertraline and fluoxetine correlated with umbilical cord concentrations of these medications.
CONCLUSIONS: Umbilical cord concentrations of antidepressants and their metabolites were almost invariably lower than corresponding maternal concentrations. Maternal doses predicted umbilical concentrations of fluoxetine and sertraline. Mean umbilical cord to maternal serum ratios were significantly lower for sertraline than fluoxetine, suggesting that sertraline may produce less fetal medication exposure than fluoxetine near delivery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727706     DOI: 10.1176/appi.ajp.160.5.993

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  94 in total

Review 1.  Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research.

Authors:  Ayesha C Sujan; A Sara Öberg; Patrick D Quinn; Brian M D'Onofrio
Journal:  J Child Psychol Psychiatry       Date:  2018-12-05       Impact factor: 8.982

Review 2.  Maternal SSRIs experience and risk of ASD in offspring: a review.

Authors:  Zainab Fatima; Aqeela Zahra; Maria Ghouse; Xu Wang; Zonghui Yuan
Journal:  Toxicol Res (Camb)       Date:  2018-07-11       Impact factor: 3.524

3.  Dose-dependent effects of neonatal SSRI exposure on adult behavior in the rat.

Authors:  Sharonda S Harris; Dorota Maciag; Kimberly L Simpson; Rick C S Lin; Ian A Paul
Journal:  Brain Res       Date:  2011-10-20       Impact factor: 3.252

Review 4.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

5.  Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings.

Authors:  Ragnhild Eek Brandlistuen; Eivind Ystrom; Malin Eberhard-Gran; Irena Nulman; Gideon Koren; Hedvig Nordeng
Journal:  Int J Epidemiol       Date:  2015-04-14       Impact factor: 7.196

6.  Treatment with selective serotonin reuptake inhibitors during pregnancy: deceleration of weight gain because of depression or drug?

Authors:  Lisa M Bodnar; Keerthy R Sunder; Katherine L Wisner
Journal:  Am J Psychiatry       Date:  2006-06       Impact factor: 18.112

7.  Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.

Authors:  Regina C Casper; Allyson A Gilles; Barry E Fleisher; Joan Baran; Gregory Enns; Laura C Lazzeroni
Journal:  Psychopharmacology (Berl)       Date:  2011-04-16       Impact factor: 4.530

8.  Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.

Authors:  John Kim; K Wayne Riggs; Shaila Misri; Nancy Kent; Tim F Oberlander; Ruth E Grunau; Colleen Fitzgerald; Dan W Rurak
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 9.  Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies.

Authors:  Shan-Yan Gao; Qi-Jun Wu; Tie-Ning Zhang; Zi-Qi Shen; Cai-Xia Liu; Xin Xu; Chao Ji; Yu-Hong Zhao
Journal:  Br J Clin Pharmacol       Date:  2017-06-10       Impact factor: 4.335

Review 10.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.